Featured News See All March 11, 2026 REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 March 5, 2026 REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights March 4, 2026 REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Year All20262025202420232022202120202019201820172016201520142013201220112009 Mar 11, 2026 REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 Mar 05, 2026 REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights Mar 04, 2026 REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Mar 02, 2026 REGENXBIO to Participate in Upcoming Investor Conferences Feb 25, 2026 REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights Feb 09, 2026 REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II Jan 28, 2026 REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
Mar 11, 2026 REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
Mar 05, 2026 REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Mar 04, 2026 REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Feb 25, 2026 REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
